Voronoi Receives Thai Phase 1b/2 IND Approval for VRN11... Expands Global Clinical Trial
2026.09.14
■ Clinical trial to be conducted at two large medical institutions in Thailand
Voronoi (310210) announced through a disclosure on the 14th that the global Phase 1b/2 IND (clinical trial plan) for 'VRN11,' its next-generation EGFR targeted therapy, has been approved by the Thai Food and Drug Administration (FDA Thailand).
With this approval, Thailand has been added to VRN11's global Phase 1b/2 clinical network. Voronoi plans to conduct global clinical trials in Australia, Hong Kong, Singapore, Malaysia, Thailand, and elsewhere, and to continue securing efficacy and safety data on VRN11 across diverse patient groups.
The Thai trial will be conducted at two major medical institutions: Phramongkutklao Hospital and Songklanagarind Hospital (Prince of Songkla University). Professor Naiyarat Prasongsook and Professor Sarayut Geater will participate as Principal Investigators (PIs).
VRN11 is a next-generation EGFR mutation targeted therapy under development for EGFR mutation non-small cell lung cancer, and has demonstrated an antitumor effect and an excellent safety profile in the previously conducted Phase 1a trial.
Clinical development is currently being expanded to treatment-naïve patients in Australia, Hong Kong, Singapore, Malaysia, Thailand, and elsewhere to also confirm its potential as a first-line treatment.
Voronoi (310210) announced through a disclosure on the 14th that the global Phase 1b/2 IND (clinical trial plan) for 'VRN11,' its next-generation EGFR targeted therapy, has been approved by the Thai Food and Drug Administration (FDA Thailand).
With this approval, Thailand has been added to VRN11's global Phase 1b/2 clinical network. Voronoi plans to conduct global clinical trials in Australia, Hong Kong, Singapore, Malaysia, Thailand, and elsewhere, and to continue securing efficacy and safety data on VRN11 across diverse patient groups.
The Thai trial will be conducted at two major medical institutions: Phramongkutklao Hospital and Songklanagarind Hospital (Prince of Songkla University). Professor Naiyarat Prasongsook and Professor Sarayut Geater will participate as Principal Investigators (PIs).
VRN11 is a next-generation EGFR mutation targeted therapy under development for EGFR mutation non-small cell lung cancer, and has demonstrated an antitumor effect and an excellent safety profile in the previously conducted Phase 1a trial.
Clinical development is currently being expanded to treatment-naïve patients in Australia, Hong Kong, Singapore, Malaysia, Thailand, and elsewhere to also confirm its potential as a first-line treatment.